CHICAGO – Exicure , Inc. (NASDAQ:), a biotechnology firm, has been notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC that its common stock faces suspension and delisting.
The company failed to file its annual report for the year ended December 31, 2023, and its first-quarter report for 2024 by the extended deadline of May 20, 2024. Moreover, Exicure has not held its 2023 Annual Meeting of Stockholders, further contributing to the delisting notice.
The suspension of trading on The Nasdaq Capital Market is set to commence on May 30, 2024, if Exicure does not appeal by May 28, 2024. An appeal would stay the suspension for 15 days from the request date, and the company plans to seek an extended stay during the hearings process. However, there is no guarantee that an extension will be granted.
Exicure’s management is actively working to complete and file the overdue Form 10-K and the Q1 Form 10-Q as soon…
